Source-grounded facts extracted from SAB Biotherapeutics, Inc.'s SEC 8-K filings across all families, newest first. Each cites a verbatim SEC excerpt.
SAB Biotherapeutics, Inc. shareholders approved Ratify the appointment of EisnerAmper LLP as the independent registered public accounting firm of the Company for the fiscal year ending December 31, 2026 at the 2026-06-18 meeting.
“Proposal 2: Ratification of the appointment of EisnerAmper LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2026 Votes For Votes Against Abstentions 59,319,363 3,373 26,798”
SAB Biotherapeutics, Inc. shareholders approved Election of Dr. David Zaccardelli, Pharm.D., Katie Ellias, David Link, MBA, and Andrew Moin, as Class II directors to serve for a term of three years at the 2026-06-18 meeting.
“Proposal 1 : Election of four Class II directors Director Votes For Withheld Broker Non-Votes David Zaccardelli, Pharm.D. 48,352,114 2,984 10,994,436 David Link, MBA 44,083,923 4,271,175 10,994,436 Katie Ellias 48,350,086 5,012 10,994,436 Andrew Moin 44,157,704 4,197,394 10,994,436”
SAB Biotherapeutics, Inc. entered into Master Manufacturing Services Agreement with Emergent BioSolutions Canada Inc. valued at minimum aggregate spend following any FDA approval equal to $36 million (effective 2026-04-28).
“On April 28, 2026 (the “Effective Date”), SAB Biotherapeutics, Inc., a Delaware corporation (the “Company” or “SAB BIO”) entered into a Master Manufacturing Services Agreement (the “MSA”) with Emergent BioSolutions Canada Inc. (“Emergent”).”
SAB Biotherapeutics, Inc. entered into Underwriting Agreement with Jefferies LLC, UBS Securities LLC, Citigroup Capital Markets, Inc. and Barclays Capital Inc. valued at underwritten offering of common stock and pre-funded warrants (effective 2026-03-17).
“On March 17, 2026, SAB Biotherapeutics, Inc. (the “Company” or “SAB”) entered into an underwriting agreement (the “Underwriting Agreement”) with Jefferies LLC, UBS Securities LLC, Citigroup Capital Markets, Inc. and Barclays Capital Inc. (collectively, the “Representatives”) as the representatives of the several underwriters named therein (the “Underwriters”), relating to an underwritten offering (the “Offering”) of (i) 19,324,677 shares (the “Firm Shares”) of the Company’s common stock, $0.0001 par value per share (the “Common Stock”), at a price to the public of $3.85 per Firm Share, and (ii) pre-funded warrants to purchase up to 2,753,246 shares of Common Stock (the “Pre-Funded Warrants”), and such shares issuable upon the exercise of the Pre-Funded Warrants (the “Warrant Shares”), at a price to the public of $3.8499 per Pre-Funded Warrant, which represents the per share public offering price for the Firm Shares less the $0.0001 per share exercise price for each such Pre-Funded Warr”
SAB Biotherapeutics, Inc.: Filed Certificate of Designations creating Series B Convertible Preferred Stock (effective 2025-07-21).
“Pursuant to the terms of the Securities Purchase Agreement, on July 21, 2025, the Company filed the Certificate of Designations with the Delaware Secretary of State designating 2,811,429 shares of its authorized and unissued preferred stock as Series B Convertible Preferred Stock.”
SAB Biotherapeutics, Inc. incurred lease obligation with Sanford Health maturing five years ending on December 31, 2029.
“(the “Company”) entered into a lease agreement, dated and effective February 1, 2025 (the “Sanford Lease Agreement”), with Sanford Health, a South Dakota non-profit corporation ( the “Landlord”). The Sanford Lease Agreement provides for a lease area of 21,014 from the Landlord to the Company, located at 2301 East 60th Street North, Sioux Falls, South Dakota 57104.”
Mark Conley changed role as Vice President of Finance at SAB Biotherapeutics, Inc..
“Mark Conley, who has been serving as Interim Chief Financial Officer since June 4, 2024, will reassume his prior position as the Company’s Vice President of Finance.”
Lucy To was appointed as Chief Financial Officer at SAB Biotherapeutics, Inc..
“On July 26, 2024, Lucy To, 38, was appointed Chief Financial Officer of SAB Biotherapeutics, Inc., a Delaware corporation (“SAB BIO” or the “Company”), with a start date of August 12, 2024.”
Mark Conley was appointed as Interim Chief Financial Officer at SAB Biotherapeutics, Inc..
“On May 30, 2024, Mark Conley, 62, was appointed Interim Chief Financial Officer of SAB Biotherapeutics, Inc., a Delaware corporation (the “Company”), effective June 4, 2024.”
Michael King, Jr. resigned as Chief Financial Officer at SAB Biotherapeutics, Inc..
“On May 26, 2024, Michael King, Jr., Chief Financial Officer of the Company, informed the Company that he will resign from his position with the Company, effective June 4, 2024, to pursue another opportunity.”
Dr. Jay S. Skyler was appointed as Class I director at SAB Biotherapeutics, Inc..
“On May 3, 2024, the Nominating and Corporate Governance Committee (the “ Committee ”) of the Board of Directors (the “ Board ”) of SAB Biotherapeutics, Inc., a Delaware corporation (the “ Company ”), recommended the appointment of, and the Board subsequently appointed, Dr. Jay S. Skyler to serve as a Class I director of the Company, effective as of May 3, 2024, and to serve until the Company’s 2025 annual meeting of stockholders or until Dr. Skyler’s successor is duly elected and qualified.”
SAB Biotherapeutics, Inc. reported the year and quarter ended December 31, 2023 results: net income net loss of $42.2 million.
“SAB Biotherapeutics Reports Full Year 2023 Operating and Financial Results”
Samuel J. Reich was appointed as Chief Executive Officer at SAB Biotherapeutics, Inc..
“On January 30, 2024, Samuel J. Reich, age 49, the Executive Chairman of the Board of Directors (the “Board”) of SAB Biotherapeutics, Inc. (the “Company”), was appointed Chief Executive Officer of the Company, effective immediately.”
SAB Biotherapeutics, Inc. entered into Controlled Equity OfferingSM Sales Agreement with Cantor Fitzgerald & Co. valued at $20,000,000 (effective 2024-01-26).
“On January 26, 2024, SAB Biotherapeutics, Inc. (the “Company”) entered into a Controlled Equity OfferingSM Sales Agreement (the “Agreement”) with Cantor Fitzgerald & Co. (the “Agent”). In accordance with the terms of the Agreement, pursuant to the Prospectus Supplement (as defined below), the Company may offer and sell from time to time through or to the Agent, as sales agent, the Company’s common stock, par value $0.0001 per share, having an aggregate offering price of up to $20,000,000 (the “Placement Shares”).”
SAB Biotherapeutics, Inc.: Filed Certificate of Amendment to effect a 1-for-10 reverse stock split of common stock (effective 2024-01-02).
“On January 2, 2024, the Company filed a Certificate of Amendment (the “Certificate of Amendment”) to amend the Company’s certificate of incorporation, as amended and restated (the “Charter”), with the Secretary of State of the State of Delaware to effect the Reverse Stock Split.”
SAB Biotherapeutics, Inc. shareholders approved Reverse Stock Split Proposal to authorize the Board to amend the Charter to effect a reverse stock split.
“Stockholders approved a proposal to authorize the Board, in its discretion but prior to the one-year anniversary of the date on which the proposal is approved by the Company’s stockholders at the Special Meeting, to amend the Charter to effect a reverse stock split of all of the outstanding shares of the Common Stock, at a ratio in the range of 2-for-3 to 1-for-10, with such ratio to be determined by the Board. This Proposal 1 is referred to as the “Reverse Stock Split Proposal”. The voting results were as follows: Votes For Votes Against Abstentions 59,076,836 3,409,403 28,811”
SAB Biotherapeutics, Inc.: Increased authorized shares of common stock from 490,000,000 to 800,000,000 (effective 2023-11-22).
“On November 22, 2023, the Company held a Special Meeting of Stockholders (the “Special Meeting”). At the Special Meeting, the stockholders of the Company approved an amendment to the Company’s Amended and Restated Certificate of Incorporation to increase the authorized number of shares of common stock, par value $0.0001 per share (the “Common Stock”) from 490,000,000 shares to 800,000,000 shares. The increase in the authorized number of shares of the Common Stock was effected pursuant to a Certificate of Amendment to the Amended and Restated Certificate of Incorporation (the “Certificate of Amendment”) filed with the Secretary of State of the State of Delaware on November 22, 2023 and was effective as of such date.”
SAB Biotherapeutics, Inc. shareholders approved Potential issuance in excess of 19.99% of outstanding Common Stock upon conversion of Series A Preferred Stock.
“Proposal 2 . Stockholders approved the potential issuance in excess of 19.99% of the Company’s outstanding Common Stock upon the conversion of the Company’s Series A-1 Convertible Preferred Stock, par value $0.0001 per share (the “Series A-1 Preferred Stock”), Series A-2 Convertible Preferred Stock, par value $0.0001 per share (the “Series A-2 Preferred Stock”), and Series A-3 Convertible Preferred Stock, par value $0.0001 per share (the “Series A-3 Preferred Stock” and, together with the Series A-1 Preferred Stock and Series A-2 Preferred Stock, the “Series A Preferred Stock”) at less than the “minimum price” under Nasdaq Listing Rule 5635(d), and which may deemed a “change of control” under Nasdaq Listing Rule 5635, pursuant to the terms of the Certificate of Designation of Preferences, Rights and Limitations of Series A Convertible Voting Preferred Stock governing the Series A Preferred Stock. The voting results were as follows: Votes For Votes Against Abstentions Broker Non Votes 3”
SAB Biotherapeutics, Inc. shareholders approved Amendment to increase authorized shares from 490,000,000 to 800,000,000.
“Proposal 1. Stockholders approved the amendment of the Company’s Amended and Restated Certificate of Incorporation to increase the total number of shares of Common Stock authorized for issuance from 490,000,000 shares to 800,000,000 shares. The voting results were as follows: Votes For Votes Against Abstentions 40,768,042 1,732,365 375,532”
Helen Katherine Ellias was appointed as Class II Director at SAB Biotherapeutics, Inc..
“recommended the appointment of, and the Board subsequently appointed, Ms. Helen Katherine Ellias to serve as a Class II director of the Company, effective as of November 20, 2023 until the Company’s 2026 annual meeting of stockholders”
Russell P. Beyer departed as Chief Financial Officer at SAB Biotherapeutics, Inc..
“Russell P. Beyer ceased to serve as Chief Financial Officer of the Company on October 27, 2023.”
Michael King was appointed as Chief Financial Officer at SAB Biotherapeutics, Inc..
“Michael King, age 62, was appointed Chief Financial Officer of SAB Biotherapeutics, Inc., a Delaware corporation (the “Company”), effective October 30, 2023.”
SAB Biotherapeutics, Inc.: Filed Certificate of Designation creating Series A-1, A-2, and A-3 Convertible Preferred Stock with specified rights, preferences, and limitations (effective 2023-10-02).
“On October 2, 2023, the Company filed the Certificate of Designation with the Delaware Secretary of State designating 78,000 shares of its authorized and unissued preferred stock as Series A-1 Preferred Stock, 78,000 shares as Series A-2 Preferred Stock and 252,000 shares as Series A-3 Convertible Preferred Stock”
SAB Biotherapeutics, Inc. entered into Securities Purchase Agreement with certain accredited investors valued at aggregate offering price of $7.5 million; aggregate exercise prices of approximately $70.5 million, (effective 2023-09-29).
“On September 29, 2023, SAB Biotherapeutics, Inc. (the " Company ") entered into a securities purchase agreement (the " Securities Purchase Agreement ") with certain accredited investors (the " Investors "), pursuant to which the Company agreed to issue and sell, in a private placement (the " Offering "), (i) 7,500 shares of Series A-1 Convertible Preferred Stock, par value $0.0001 per share, for an aggregate offering price of $7.5 million (the " Series A-1 Preferred Stock "), (ii) tranche A warrants (the " Preferred Tranche A Warrants ") to acquire shares of Series A-1 Preferred Stock or Series A-3 Preferred Stock, par value $0.0001 per share, for an aggregate exercise price of $70.5 million (the " Series A-3 Preferred Stock "), (iii) tranche B warrants to acquire shares of Series A-3 Preferred Stock, par value $0.0001 per share, for an aggregate exercise price of $52.0 million (the " Preferred Tranche B Warrants "), and (iv) tranche C warrants to purchase Series A-3 Preferred Stock, p”
Andrew D. Moin was appointed as Director at SAB Biotherapeutics, Inc..
“the Company’s Board of Directors approved the appointment of Andrew D. Moin, of Sessa Capital (Master), L.P., to the Company’s Board of Directors, effective upon the closing of the Offering.”
SAB Biotherapeutics, Inc. engaged EisnerAmper LLP as its auditor.
“On August 18, 2023, SAB Biotherapeutics, Inc. (the "Company") engaged EisnerAmper LLP ("EisnerAmper") as the Company's independent public accounting firm”
Mayer Hoffman McCann P.C. resigned as auditor of SAB Biotherapeutics, Inc..
“On July 25, 2023, Mayer Hoffman McCann P.C. (“MHM”) informed SAB Biotherapeutics, Inc. (the “Company”) and the Audit Committee of the Company’s Board of Directors that it would not stand for re-election as the Company’s independent registered public accounting firm for the audit of the Company’s financial statements for the fiscal year ending December 31, 2023.”
SAB Biotherapeutics, Inc. shareholders approved Ratify the appointment of Mayer Hoffman McCann P.C. as independent registered public accounting firm at the 2023-06-29 meeting.
“Proposal 2: Ratify the appointment of Mayer Hoffman McCann P.C. as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2023 Votes For Votes Against Abstentions 37,253,986 33,433 235,486”
SAB Biotherapeutics, Inc. shareholders approved Election of two Class II directors at the 2023-06-29 meeting.
“Proposal 1: Election of two Class II directors Director Votes For Withheld Broker Non-Votes Jeffrey G. Spragens 30,399,580 403,139 6,720,186 David Link 30,402,160 400,559 6,720,186”
Erick Lucera was appointed as Director at SAB Biotherapeutics, Inc..
“the Board subsequently appointed, Mr. Erick Lucera to serve as a director of the Company, effective as of April 3, 2023”
SAB Biotherapeutics, Inc. updated its full year ended December 31, 2022 guidance (reaffirmed).
“On March 31, 2023, SAB Biotherapeutics, Inc., a Delaware corporation (the “Company”) issued a press release announcing its financial results for the year ended 2022.”
SAB Biotherapeutics, Inc. reported that prior financial statements should not be relied upon.
“in the Company's Quarterly Reports on Forms 10-Q for the three months ended March 31, 2022, the six months ended June 30, 2022, and nine months ended September 30, 2022 (the “Prior Period Interim Financial Statements”), should no longer be relied upon as a result of the following accounting errors: ● The Company concluded that it did not correctly account for a financed insurance premium whereby a third-party lender prepaid the Company's annual insurance premiums to our insurance companies in exchange for a short-term interest bearing note (the “Insurance Financing Agreement”). The Company previously recognized, on its consolidated balance sheet, a current prepaid asset for the amount paid by the Company under the Insurance Financing Agreement in excess of the total amortized value of the prepaid insurance policy. The Company reassessed its accounting for the Insurance Financing Agreemen”
SAB Biotherapeutics, Inc. incurred debt of pay $1.5 million to Ladenburg in cash or shares of common stock, at the Company’s option; and (ii) no later than Decembe with Ladenburg Thalmann & Co. Inc. maturing December 31, 2023.
“On March 21, 2023, SAB Biotherapeutics, Inc., a Delaware corporation (the “Company”) entered into a settlement agreement with Ladenburg Thalmann & Co. Inc. (the “2023 Ladenburg Agreement”, and the action brought by Ladenburg, the “Ladenburg Action”), effective March 23, 2023.”
SAB Biotherapeutics, Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5450(a)(1)).
“January 23, 2023, SAB Biotherapeutics, Inc. (the "Company") received a written notification (the “Notice Letter”) from The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that we were not in compliance with Nasdaq Listing Rule 5450(a)(1), as the closing bid price for our common stock was below the $1.00 per share requirement for the last 30 consecutive business days. The Notice Letter stated that we have 180 calendar days, or until July 24, 2023 (the “Initial Compliance Period”), to regain compliance with the minimum bid price requirement. If we do not regain compliance by the end of”
SAB Biotherapeutics, Inc. entered into Securities Purchase Agreement with certain institutional and accredited investors valued at approximately $8.0 million (effective 2022-12-06).
“On December 6, 2022, SAB Biotherapeutics, Inc. (the “Company” or “SAB”) entered into a Securities Purchase Agreement (the “Purchase Agreement”) with certain institutional and accredited investors”
SAB Biotherapeutics, Inc. entered into Right of First Refusal Agreement with Emergent BioSolutions Canada, Inc. (effective 2022-10-26).
“On October 26, 2022, SAB Biotherapeutics, Inc., a Delaware corporation (the “Company”) entered into a Manufacturing Option Agreement (the “Manufacturing Agreement”) and Right of First Refusal Agreement (the “RoFR Agreement,” and together with the Manufacturing Agreement, the “Agreements”) with Emergent BioSolutions Canada, Inc., a wholly-owned subsidiary of Emergent BioSolutions Inc. (“Emergent”).”
SAB Biotherapeutics, Inc. entered into Manufacturing Option Agreement with Emergent BioSolutions Canada, Inc. (effective 2022-10-26).
“On October 26, 2022, SAB Biotherapeutics, Inc., a Delaware corporation (the “Company”) entered into a Manufacturing Option Agreement (the “Manufacturing Agreement”) and Right of First Refusal Agreement (the “RoFR Agreement,” and together with the Manufacturing Agreement, the “Agreements”) with Emergent BioSolutions Canada, Inc., a wholly-owned subsidiary of Emergent BioSolutions Inc. (“Emergent”).”
Charles H. Randall resigned as Chief Strategy Officer at SAB Biotherapeutics, Inc..
“On December 31, 2021, Charles H. Randall, Chief Strategy Officer of SAB Biotherapeutics, Inc. (the “Company”), resigned.”
Samuel J. Reich was appointed as Executive Chairman of the Board of Directors at SAB Biotherapeutics, Inc..
“On November 17, 2021, and effective as of October 25, 2021, SAB Biotherapeutics, Inc., a Delaware corporation (the “Company”) entered into an Executive Employment Agreement with Mr. Samuel J. Reich (the “Agreement”) to serve as the Company’s Executive Chairman of the Board of Directors.”
Thomas Luke was appointed as Chief Medical Officer at SAB Biotherapeutics, Inc..
“Thomas Luke, MD 59 Chief Medical Officer”
Charles H. Randall, Jr. was appointed as Chief Strategy Officer at SAB Biotherapeutics, Inc..
“Charles H. Randall, Jr., MBA 58 Chief Strategy Officer”
Russell Beyer was appointed as Chief Financial Officer at SAB Biotherapeutics, Inc..
“Russell Beyer 66 Chief Financial Officer”
David Link was appointed as Director at SAB Biotherapeutics, Inc..
“David Link 66 Class II Director”
William Polvino was appointed as Director at SAB Biotherapeutics, Inc..
“William Polvino, MD 61 Class I Director”
Jeffrey G. Spragens was appointed as Director at SAB Biotherapeutics, Inc..
“Jeffrey G. Spragens 79 Class II Director”
Mervyn Turner was appointed as Director at SAB Biotherapeutics, Inc..
“Mervyn Turner, PhD 74 Class I Director”
Eddie J. Sullivan was appointed as President and Chief Executive Officer at SAB Biotherapeutics, Inc..
“Eddie J. Sullivan, PhD 55 Class III Director, President and Chief Executive Officer”
Christine Hamilton was appointed as Director at SAB Biotherapeutics, Inc..
“Christine Hamilton, MBA 65 Class III Director”
Samuel J. Reich was appointed as Executive Chairman at SAB Biotherapeutics, Inc..
“Samuel J. Reich 46 Class III Director and Executive Chairman of the Board”
Samuel J. Reich departed as Executive Officer at SAB Biotherapeutics, Inc..
“Effective upon the Closing, each of James Martin, Ilan Katz and Stephen D. Collins, MD, PhD. ceased serving as a director of BCYP and Samuel J. Reich ceased serving as an executive officer of BCYP.”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.